Multiple large varieties, over-consistent evaluation (with list)

Pharmaceutical Network January 21st, many of the industry's attention to large varieties, over-consistent evaluation.
, NMPA's official website released january 18, 2021 drug approval documents to be received information, 18 pharmaceutical agents through a consistent evaluation, involving 14 pharmaceutical companies.
, there are many industry concerns about the large varieties over-consistent evaluation.
: Two years later, in the drug information released on January 18th, Hengrui's hydrochloric acid right metomide injection was evaluated by the quality of generic drugs and the consistency of efficacy. according to
data, hydrochloric acid right metomy is a relatively selective alpha2-epinephrine-perder agonist suitable for sedation during tracheal intination and mechanical ventilation in surgical patients undergoing general anaesthetic, sedation for patients who start intestion during intensive care and use a ventilator.
hydrochloric acid right metomide injection was developed jointly by Oricon Pharma and Abbott, and was first approved by the FDA in December 1999 under the ®.
follow-up in the European Union, Japan and other countries and regions listed for sale.
Hengrui Pharmaceuticals in 2009 took the lead in the domestic listing of hydrochloric acid right metomide injection, the trademark is Abein.
2019, China's public medical institutions terminal sales of more than 3.5 billion yuan.
data show that since 2009, Hengrui Pharmaceuticals first listed right-to-metomed, the domestic market sales growth is rapid, in 2017 hospital sales have reached 1.8 billion yuan.
After 2011, Jiangsu Enhua Pharmaceuticals, Sichuan Guorui Pharmaceuticals, Chenxin Pharmaceuticals, three enterprises of the right metomi is set to be listed, in 2018, Hunan Colum, Yangzijiang Pharmaceuticals, Shandong Hilkangtai, Yichang Renfu varieties have been approved, the variety competition intensified.
, Yangzijiang Pharmaceuticals was the first to pass a consistent evaluation of the variety, and in 2018 became the only company to participate in the 4 plus 7 collection, no competitors.
was able to win the bid at a very small price, which also made Yangzijiang Pharmaceuticals in the specific implementation process, sales and sales trends are basically the same.
from the data, the market share of Yangzijiang city is basically 0 by 2019, whether it is 1mL or 2mL specifications.
the implementation of the 4 plus 7, Yangzijiang City's share of the rapid increase.
the fourth quarter of 2019, the 1mL and 2mL specifications accounted for 30.99% and 88.00% of sales, respectively.
, which was previously a higher proportion, faced a sharp drop in sales.
To some extent, consistency evaluation is the national collection of tickets, but also to retain market share of the necessary conditions, such as Yangzijiang Pharmaceuticals, by virtue of the volume of procurement to achieve the sale of varieties of curved over-cars.
two years after the 4-plus-7 episode, Hengrui Pharma finally passed a consistent evaluation, whether it will achieve headwinds in the future, Cypress Blue will remain concerned.
1.6 billion varieties, the first review according to the NMPA released the news, Colon Pharmaceuticals medium / long chain fat emulsion (C8-24) the first through a consistent evaluation, the product is an extraintestinal nutrition drug.
2019, china's public medical institutions in the terminal sales of this variety of more than 1.6 billion yuan.
Koren Pharmaceuticals announcement shows that medium/long-chain fat emulsion is the most widely used fatty milk in clinical practice, with rapid energy supply, high efficiency nitrogen saving, liver protection and other advantages, has been widely recommended by domestic and foreign guidelines for liver function damage and tumors and other patients.
same time, according to the Mienet Consistency Evaluation Database, Colum Pharmaceuticals' fatty lactates (17) glucose (11%) injections, fatty lactates (17) glucose (19%) injections , compound amino acids (16AA-II.)/glucose (48%) electrolyte injections, medium/long-chain fat emulsions (C8-24Ve) and other 4 products have passed the consistent evaluation.
The fourth batch of collection varieties, injection evaluation is worth noting that Osaikang's injection of 3 types of generic drugs with tamoxiamine market application was approved and treated as a review, the variety of oral regular release agent type has been included in the fourth batch of national collection catalog.
According to CPhI Pharmaceuticals Online, tymoazine is a new generation of metazine compounds, bioutivity close to 100%, fat solubility, small molecular weight, can quickly pass through the blood-brain barrier, absorption quickly, completely, average 0.5-1.5 hours to reach the peak concentration of blood medicine.
was first developed by Aston University in the United Kingdom, and then obtained the sole development rights of the product in most of the world's markets by Shilling-Ya Pharmaceuticals of Germany, and has been listed in capsules and injections two dosage forms.
2018, sales of this variety in China's public medical institutions exceeded 2 billion yuan, a growth rate of 17.89 percent, according to Milnet data, and growth has slowed in the last two years.
At present, the domestic market has capsules and injections, of which, the capsule evaluation enterprises have Tianshili, shuangli pharmaceutical industry, and has been included in the fourth batch of national collection catalog, will be the original study of Merca East collection bid.
the first review in 2019, Ossercon was also approved for the new classification after he was first evaluated in the injection competition.
as of January 18, according to the statistics of drug news Kanze, there have been 1767 standard drugs through the consistent evaluation.
With the enterprise's product consistency evaluation layout into the harvest period, there will be more and more varieties in line with the national conditions of collection, and collection has become normal to twice a year, these moving more than 1 billion varieties, will usher in a new round of shuffle period.